Celltrion's 'Zimtentra' Targets Arthritis Market Beyond Gastrointestinal Diseases

Submission of Phase 3 Clinical Trial Plan for Rheumatoid Arthritis Target
'Remsima SC' Already Approved and Prescribed
Target Market Expected to Expand from $10 Billion to $40 Billion

Celltrion has initiated the expansion of the indication for its autoimmune disease treatment new drug, Jimpendra, to include rheumatoid arthritis.

Celltrion's new autoimmune disease treatment drug 'Jimpentra'
[Photo by Celltrion]

On the 18th (local time), Celltrion announced on the 19th that it had submitted a Phase 3 clinical trial plan for Jimpendra targeting rheumatoid arthritis patients to the U.S. Food and Drug Administration (FDA). The clinical trial will involve a total of 189 rheumatoid arthritis patients, divided into Jimpendra and placebo groups, and will compare and analyze efficacy, safety, and pharmacokinetic characteristics over 52 weeks.

Rheumatoid arthritis is a type of autoimmune disease in which the body's immune system attacks healthy joint tissues, causing joint pain, swelling, stiffness, and loss of function. According to IQVIA, a pharmaceutical market research firm, the global rheumatoid arthritis treatment market was valued at $42.351 billion (approximately 55 trillion KRW) last year, with the U.S. market accounting for about 72%, or $30.487 billion (approximately 40 trillion KRW). This market size is three times larger than the inflammatory bowel disease market, including ulcerative colitis and Crohn's disease, which are the current indications for Jimpendra, based on the U.S. market.

The active ingredient in Jimpendra, infliximab, has long been used to treat various autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease. Both Celltrion's Remsima and Remsima SC have rheumatoid arthritis indications in most global regions. In particular, Remsima SC has already demonstrated related efficacy, safety, and superiority through clinical trials and post-analysis results targeting rheumatoid arthritis patients at numerous international conferences.

However, since Jimpendra is entering the U.S. market as a new drug for the first time, it initially focused on inflammatory bowel disease and secured indications only for ulcerative colitis and Crohn's disease. Celltrion plans to add rheumatoid arthritis to Jimpendra's indications through this clinical trial and rapidly expand its influence in the global market. If the rheumatoid arthritis indication is secured following inflammatory bowel disease, the target market for Jimpendra is expected to grow from the current $10.3 billion level to $40.8 billion (approximately 53 trillion KRW).

Jimpendra has been smoothly settling into the market, being listed as a preferred drug in formularies of major Pharmacy Benefit Managers (PBMs) shortly after its U.S. launch. Celltrion intends to actively expand its market share through various marketing activities and channel expansion.

A Celltrion official stated, “With the submission of this clinical trial plan, Jimpendra is reaching an important milestone in expanding its market in the U.S., and we will make company-wide efforts to ensure the clinical trial leads to successful results. Once the rheumatoid arthritis indication is added, not only will Jimpendra’s target market in the U.S. expand, but the product’s competitiveness will also be strengthened, accelerating Celltrion’s growth.”

This content was produced with the assistance of AI translation services.